COSTS OF PEN (NOVOPEN® 3) VERSUS SYRINGE IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 - A PHARMACOECONOMIC STUDY FROM THE SLOVAK REPUBLIC
Author(s)
Jan Bielik, MD, PhD, AssProf, Head1, Noman Ehsan, MD, Physician2, Jozef Lacka, MD, PhD, Medical manager3, Miroslav Pastucha, MD, Director41Trencin University, TrenÄÃn, Slovak Republic; 2 Private diabetology out-clinic dpt, Nové Mesto nad Váhom, Slovak Republic; 3 Novo Nordisk A/S, Bratislava, Slovak Republic; 4 General Health Insurance Company, Trencin, Slovak Republic
Objective: There is a practically stable 5.3 % prevalence of diabetes mellitus (DM) in Slovakia. The treatment ratio was as follows: 47.6 % patients are on diet, 30.8 % on PAD and 21.6 % on insulin. The main objective of this study was to determine if the intensified insulin therapy with insulin pen is cost-effective compared to conventional therapy. Methods: Direct medical an non direct costs were evaluated in retrospective randomized study in patients with DM type 2. A group of 48 patients on intensified insulin therapy (IIT) was compared with a group of 28 patients treated with conventional therapy (CT). Results: The average duration of DM was 113.51 months in IIT group and 147.67 months in CT group. The significant difference (p<0.05,s) was observed in age (53.19 in IIT vs 55.11 in CT) and in serum cholesterol (6.14 in ITT vs 6.65 in CT). The hospital costs were higher in IIT: €568 vs. €511 in CT. The laboratory costs were lower in IIT: €133 vs. €167 in CT. IIT had higher costs for reimbursed drugs, glucometers and insulin pens by Health Insurance Companies: €1065 vs. €1024 in CT. No statistical difference was recorded in co-payments: €99 in IIT vs. €100 in CT. Indirect patients costs based on time loss were €185 in IIT vs. €227 in CT. The total costs per patient per year were €1972 in IIT vs. €1964 in CT. Conclusion: The treatment of DM type 2 with insulin pen NovoPen® 3 is clinically and economically effective in comparison to the treatment with syringe. The estimated costs of LYS are €4759 in men and €6519 in women per patient with DM in Slovakia.
Conference/Value in Health Info
2008-05, ISPOR 2008, Toronto, Ontario, Canada
Value in Health, Vol. 11, No. 3 (May/June 2008)
Code
PDB15
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders